What question did this study set out to answer?

This research examines the prevalence and impact of biomarker testing in patients with metastatic non-small cell lung cancer (mNSCLC).

February 8, 2026The American Journal of Managed Care0 citations

Real-world insights on biomarker testing patterns and implications for mNSCLC therapy selection

ASAmy E. StanfordAstraZeneca (Switzerland)SBShawn BoykinAstraZeneca (Switzerland)KDK. N. Pannag DesaiWilmington University

Key Points

This research examines the prevalence and impact of biomarker testing in patients with metastatic non-small cell lung cancer (mNSCLC).
Analyzed testing patterns for biomarker assessments in mNSCLC patients.
Assessed disparities in access to comprehensive testing.
Evaluated the implications of testing on therapy selection and patient outcomes.
Majority of patients did not receive comprehensive biomarker testing.
Identified significant disparities in testing access.
Potential for improved therapy selection and patient outcomes with better testing adherence.

Abstract

Most patients with mNSCLC did not undergo comprehensive biomarker testing, leading to potential missed opportunities for precision therapy. Disparities in testing and treatment underscore the need for expanded access to molecular diagnostics, payer support for comprehensive testing (including liquid biopsy), and alignment with national guidelines to improve outcomes and advance equitable cancer care.

Perguntar à IA

Bookmark

View Full Paper